NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · Real-Time Price · USD
3.190
-0.060 (-1.85%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.

It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.

The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.

The company was founded in 2011 and is headquartered in Carmel, Indiana.

NeurAxis, Inc.
NeurAxis logo
Country United States
Founded 2011
IPO Date Aug 9, 2023
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Brian Carrico

Contact Details

Address:
11611 North Meridian Street, Suite 330
Carmel, Indiana 46032
United States
Phone (812) 689-0791
Website neuraxis.com

Stock Details

Ticker Symbol NRXS
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001933567
CUSIP Number 64134X201
ISIN Number US64134X2018
Employer ID 45-5079684
SIC Code 3845

Key Executives

Name Position
Brian Carrico President, Chief Executive Officer and Director
Timothy Robert Henrichs Chief Financial Officer
Dr. Adrian Miranda Senior Vice President of Science and Technology and Chief Medical Officer
Dr. Thomas Carrico Chief Regulatory Officer and Compliance and Privacy Officer
Dr. Christopher Robin Brown D.D.S. Founder, Director of Innovation and Director

Latest SEC Filings

Date Type Title
Nov 15, 2024 8-K Current Report
Nov 12, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Oct 18, 2024 8-K Current Report
Oct 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 13, 2024 8-K Current Report
Aug 21, 2024 8-K Current Report
Aug 9, 2024 10-Q Quarterly Report
Aug 9, 2024 8-K Current Report
Jul 5, 2024 8-K Current Report